(Reuters) - Amgen Inc reported higher first-quarter earnings on Tuesday, helped by price increases for its best-selling drugs, as well as lower spending on research and development.
Amgen shares, which rose 1.5 percent in regular trading, were up another 2.3 percent at $172.25 after hours.
16:37 Fitbit acquires software assets from rival Pebble13
14:31 Lost Christmas parcels 'prompt two-and-a-half-hour hunt'15
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle21